Health,
A decent place to get a better look at current data is http://www.health. gov.z a/covid-19-rapid-reviews/
CONCLUSION
As synthesized in the Cochrane systematic review and meta-analysis, the current evidence for the use of ivermectin in
COVID-19 does not suggest any clear benefits in either inpatients or outpatients with respect to mortality, clinical
improvement, or viral clearance. All domains were assessed as being of low or very low quality evidence. The included RCTs
for the most part have very small sample sizes and suffer from considerable heterogeneity with respect to ivermectin dosing
strategy and outcome measures. They also have several methodological limitations, including a lack of allocation
concealment, subjective and poorly defined endpoints and patient severity allocations, and baseline imbalances between
the various trial arms in co-administered medications and in patients with risk factors for poor outcomes. Many of the trials
included have not yet been peer-reviewed, which adds further uncertainty to the evidence base. Lastly, the potential for
publication bias cannot be excluded; several trials were only added to trial registries after their completion.
Together, these significant limitations limit the confidence in any conclusions with respect to ivermectin, and thus there is
insufficient evidence to recommend ivermectin’s use in any patient population outside a clinical trial. Further data from
large, well-designed RCTs is needed.